29 trials including 2,610 CRC patients were evolved. Compared with chemotherapy alone, the combination of chemotherapy with CIK/DC-CIK immunotherapy significantly prolonged the overall survival rate (OS) and disease-free survival rate.
A new type of immunotherapy that uses dendritic cells is being used to treat colorectal cancer. The dendritic cells are first exposed to cytokines, which stimulate them to produce killer immune cells called cytotoxic T-lymphocytes or “killer” T-cells. These killer cells are then injected into the patient’s bloodstream where they can travel to different parts of the body and attack any cancerous tissue they come in contact with.
The combination of CIK/DC-CIK immunotherapy and chemotherapy prolong CRC patients’ survival time, enhanced patients’ immune function and alleviates the adverse effects caused by chemotherapy.
Article Reference link: click here
Scientific article publishing date : 11/7/2017
Immucura identifier : BSC21_009EN